SCFAD Compounds Induce Gamma-Globin Without Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for treating hemoglobin disorders such as sickle cell disease and thalassemias are limited by their toxicity, requirement for parenteral administration, and inability to induce high-level fetal hemoglobin (HbF) expression safely and orally, failing to adequately address the clinical complications of these conditions.
Innovation Solution
Development of high-throughput screening methods to identify non-cytotoxic, FDA-approved short chain fatty acid derivatives (SCFADs) that induce γ-globin expression, including compounds like ambroxol, benserazide, desloratadine, and MS-275, which stimulate erythropoiesis and increase total hemoglobin levels without inhibiting cell proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If hydroxyurea is used to stimulate HbF production, then HbF levels increase, but toxicity and cytotoxicity occur
Solution Approach 1:
The patent changes the chemical parameters by identifying and using short chain fatty acid derivatives (SCFADs) with specific molecular structures that induce HbF production through different mechanisms than hydroxyurea. The SCFADs modify histone acetylation states to activate γ-globin gene expression, achieving HbF elevation without the cytotoxic effects of hydroxyurea.
Solution Approach 2:
The patent employs FDA-approved, orally available SCFADs that can be administered continuously without the severe toxicity requirements of hydroxyurea. These compounds represent a safer, more tolerable therapeutic alternative that maintains HbF production while eliminating the need for strict monitoring of toxic effects.
2Reliability
If parenteral administration is used to deliver therapeutic agents, then treatment efficacy is achieved, but ease of operation deteriorates
Solution Approach 1:
The patent replaces the mechanical injection system required for parenteral administration with an oral delivery system. The SCFADs are designed to be orally active, allowing patients to self-administer treatment through simple pill consumption, eliminating the need for needles, syringes, and medical supervision for injections.
Solution Approach 2:
The patent identifies compounds that serve multiple functions: they are both HbF-inducing agents and orally available medications with established safety profiles. This multi-functionality allows the same compound to achieve therapeutic efficacy while providing the convenience of oral administration, making the treatment accessible to a broader patient population.
3Quantity of substance
If high-level HbF expression is induced, then clinical complications are ameliorated, but cell proliferation is inhibited
Solution Approach 1:
The patent changes the mechanism of HbF induction by using SCFADs that act as histone deacetylase inhibitors, modifying chromatin structure to activate γ-globin transcription. This epigenetic mechanism allows high-level HbF expression without interfering with the cell cycle or inhibiting erythroid cell proliferation, unlike cytotoxic agents that achieve HbF induction through cell stress or apoptosis pathways.
Data Source
AI summary
The present invention generally relates to compositions containing chemical compounds and compositions and pharmaceutical formulations of the compounds which increase the expression of total hemoglobin or globin protein such as embryonic or fetal globin, or the proliferation of hemoglobin expressing and other blood cells. These compositions can be used to treat or prevent the symptoms associated with anemia, sickle cell diseases, thalassemia, and other blood cell deficiencies and blood disorders. The invention also relates to methods for administering these compositions to subjects and for use as medical aids for the treatment and prevention of blood and other disorders.